Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the...
Clinical trial approval / initiation
Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...
Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials
China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...
Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...
Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study
Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...
BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....
Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study
China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...
CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...
Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...
Gracell Biotechnologies Gains IND Approval for GC012F in China
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...
Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment...
Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...
Antengene Launches Phase I CLINCH Study for ATG-022 in Australia
China-based Antengene Corporation Ltd (HKG: 6996) has received approval from Australia’s Therapeutic Goods Administration (TGA)...